Devomit should be taken orally, preferably 15-30 minutes before meals. For suspension, shake well before use. Suppositories are for rectal use.

Domperidone acts as a selective peripheral dopamine D2 and D3 receptor antagonist. It increases gastrointestinal motility and tone by blocking dopamine receptors in the gut wall, thereby enhancing esophageal peristalsis, increasing lower esophageal sphincter pressure, and accelerating gastric emptying. Its antiemetic effect is due to its dopamine receptor blocking action in the chemoreceptor trigger zone (CTZ), located outside the blood-brain barrier.

• •Hypersensitivity to Domperidone or any component of the formulation.
• •Patients with known prolongation of cardiac conduction intervals (e.g., QT), particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases (e.g., congestive heart failure).
• •Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) or with other QT-prolonging drugs.
• •Prolactin-releasing pituitary tumor (prolactinoma).
• •Severe hepatic impairment.
• •Patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include somnolence, disorientation, and extrapyramidal reactions (e.g., dystonia, dyskinesia). There is no specific antidote. Treatment should be symptomatic and supportive, including gastric lavage and activated charcoal. ECG monitoring is recommended.

Pregnancy: Use of domperidone during pregnancy is not recommended unless the potential benefits outweigh the potential risks to the fetus. Lactation: Domperidone is excreted in human milk in small amounts. A risk to the breast-fed infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Devomit therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.